EGFR and breast carcinoma: Notably, immunoblot analysis revealed significantly enhanced EGFR activation in hepatotropic metastatic cells (HM3) compared to Pri cells, brain-tropic (BM3), and lung-tropic (LM3) derivatives, indicating organotropism-dependent EGFR hyperactivation in breast cancer liver metastases (Fig. S9D).